Longi Green Energy Technology Co.Ltd(601012) : signed major investment agreement, with the project investment amount of about 19.5 billion yuan
Longi Green Energy Technology Co.Ltd(601012) announced on the evening of March 13 that the company, the people’s Government of Inner Mongolia Eerduosi Resources Co.Ltd(600295) city and the people’s Government of Yijinholo banner signed the investment cooperation agreement on March 12, 2022, regarding the company’s investment and construction of 20GW monocrystalline silicon rod and chip project in mengsu economic Development Zone of Yijinholo banner, Inner Mongolia Eerduosi Resources Co.Ltd(600295) City, Inner Mongolia Autonomous Region 30GW high-efficiency single crystal cell project and 5GW high-efficiency photovoltaic module project reached a cooperation intention. The estimated investment amount of the project with an annual output of 20GW single crystal silicon rod and chip is 7.6 billion yuan, the estimated investment amount of the project with an annual output of 30GW high-efficiency single crystal cell is 10.3 billion yuan, and the estimated investment amount of the project with an annual output of 5GW high-efficiency photovoltaic module is 1.6 billion yuan.
Nanjing Vazyme Biotech Co.Ltd(688105) Nanjing Vazyme Biotech Co.Ltd(688105) the New Coronavirus antigen test kit for medical production completes the content changes of the instructions and so on,
Nanjing Vazyme Biotech Co.Ltd(688105) announced on the evening of March 13 that the wholly-owned subsidiary Nanjing Vazyme Biotech Co.Ltd(688105) medical obtained the medical device registration change document (in vitro diagnostic reagent) approved by the State Drug Administration on March 12, 2022 The New Coronavirus antigen detection kit produced by Nanjing Vazyme Biotech Co.Ltd(688105) has completed the intended use of medical device product registration, increased the sample type and the changes in the content of the instructions.
Pku Healthcare Corp.Ltd(000788) : the company has no plan to cooperate with foreign manufacturers
Pku Healthcare Corp.Ltd(000788) 3 on the evening of March 13, it was announced that the stock trading fluctuated abnormally. The company is concerned about recent media reports on the progress of oral drugs for covid-19 virus developed by yanyeyi pharmaceutical company in Japan. At present, the company has no plan to cooperate with foreign manufacturers. The company is now in the transitional period of restructuring of Founder group. For the main business and core products of the company, please refer to the annual report disclosed by the company.
Wuhan Easy Diagnosis Biomedicine Co.Ltd(002932) : the company’s covid-19 antigen detection reagent has submitted a registration application to the State Food and Drug Administration
Wuhan Easy Diagnosis Biomedicine Co.Ltd(002932) 3 announced on the evening of March 13 that stock trading fluctuated abnormally. In March 11th, according to the National Health Protection Committee, after studying, the State Council responded to the joint prevention and control mechanism of New Coronavirus pneumonia, and decided to add antigen detection on the basis of nucleic acid detection, and formulated the “COVID-19 virus antigen detection application plan”. Wuhan Easy Diagnosis Biomedicine Co.Ltd(002932) said that covid-19 nucleic acid detection reagent company mentioned in the plan had been approved in March 2020 and continued to bring sales revenue to the company; Covid-19 antigen detection reagent of the company has submitted an application for registration to the State Drug Administration, and the acquisition time of the registration certificate is still uncertain.
Bgi Genomics Co.Ltd(300676) : change of medical device registration certificate of covid-19 antigen detection products of holding subsidiary
Bgi Genomics Co.Ltd(300676) 3 on the evening of March 13, it was announced that Huada, a holding subsidiary, changed the medical device registration certificate of covid-19 antigen testing products due to its recent acquisition of the medical device registration change document of the people’s Republic of China (in vitro diagnostic reagent) issued by the State Food and drug administration. The change of the registration certificate of medical devices for covid-19 antigen detection products of Huada Yinyuan mainly refers to the change of the expected use, instructions, storage conditions and validity period of the products in accordance with the application scheme for covid-19 virus antigen detection (Trial) and other relevant national regulations.
Guangzhou Wondfo Biotech Co.Ltd(300482) : approval certificate of New Coronavirus antigen test kit changed
Guangzhou Wondfo Biotech Co.Ltd(300482) 3 announced on the evening of March 13 that it had recently received a medical device registration change document issued by the State Drug Administration. Product Name: New Coronavirus (2019-nCoV) antigen detection kit (colloidal gold method); After the change: [anticipation], the product is used for the qualitative detection of New Coronavirus N antigen in oral throat swabs, nasopharyngeal swabs and nasal swabs in vitro, and the sampling mode of nasal swabs is increased.
Beijing Oriental Yuhong Waterproof Technology Co.Ltd(002271) : increase the price of some main products of the company
Beijing Oriental Yuhong Waterproof Technology Co.Ltd(002271) 3 announced on the evening of March 13 that based on the continuous rise in the prices of main raw materials, resulting in the continuous increase of product costs, and combined with market demand and other factors, the prices of some main products of the company will be adjusted from March 16, 2022. The expected adjustment ranges are as follows: 1. Asphalt coiled material will be increased by 15% – 20%; 2. Polymer coiled material increased by about 10%; 3. Polyurethane coating increased by about 20%; 4. Water based coatings up by about 20%; 5. The increase of asphalt coating is about 20%.
3Peak Incorporated(688536) : net profit of 443 million yuan in 2021, with a year-on-year increase of 141.32%
3Peak Incorporated(688536) 3 on the evening of March 13, the annual report was disclosed, and the operating revenue in 2021 was 1.326 billion yuan, a year-on-year increase of 134.06%; The net profit was 443 million yuan, a year-on-year increase of 141.32%; The basic earnings per share is 5.54 yuan. The company plans to distribute a cash dividend of 6.14 yuan (including tax) for every 10 shares.
Meihua Holdings Group Co.Ltd(600873) : net profit in 2021 increased by 139% year on year
Meihua Holdings Group Co.Ltd(600873) 3 on the evening of March 13, the annual report was disclosed. In 2021, the operating revenue was 22.837 billion yuan, an increase of 33.94% year-on-year, and the net profit attributable to the owner of the parent company was 2.351 billion yuan, an increase of 139.40% year-on-year; It is proposed to distribute cash dividend of 4.0 yuan (including tax) to all shareholders for every 10 shares.
Jiangsu Yitong High-Tech Co.Ltd(300211) : net profit of 28.46 million yuan in 2021, with a year-on-year increase of 208%
3 Hunan Tianrun Digital Entertainment & Cultural Media Co.Ltd(002113) disclose the annual report on the evening of March 13. In 2021, the operating revenue was 250 million yuan, with a year-on-year increase of 206.83%; The net profit was 28.46 million yuan, a year-on-year increase of 208.36%.
The basic earnings per share is 0.0940 yuan. It is proposed to distribute a cash dividend of 0.14 yuan (including tax) to all shareholders for every 10 shares.
Asymchem Laboratories (Tianjin) Co.Ltd(002821) : the operating revenue in the first quarter is expected to increase by more than 150% year-on-year
Asymchem Laboratories (Tianjin) Co.Ltd(002821) 3 announced on the evening of March 13 that the company has maintained a strong growth momentum this year. While continuing to undertake large orders, the business of other sectors showed a momentum of accelerated growth. The scale of orders on hand and the growth of revenue from January to February reached a record high. According to the preliminary accounting of the company, the operating revenue from January to February increased by more than 130% year-on-year. The company expects that the operating revenue in the first quarter of 2022 will increase by more than 150% year-on-year, with an amount of more than 2 billion yuan.
Baolingbao Biology Co.Ltd(002286) : the net profit from January to February was about 26 million yuan, reversing the loss year-on-year
Baolingbao Biology Co.Ltd(002286) 3 announced on the evening of March 13 that the company had a good start in production and operation from January to February and achieved good business results. According to the preliminary accounting of the company, from January to February 2022, the company achieved an operating revenue of about 401 million yuan, an increase of about 20.89% over the same period last year; The net profit attributable to the shareholders of the listed company was about 26 million yuan, with a loss of 4.1686 million yuan in the same period last year.
Jiangsu Eastern Shenghong Co.Ltd(000301) : net profit in 2021 increased by 490% year on year
Jiangsu Eastern Shenghong Co.Ltd(000301) 3 on the evening of March 13, the performance express was released. In 2021, the total operating revenue was 51.6 billion yuan, a year-on-year increase of 53.24%; The net profit was 4.523 billion yuan, a year-on-year increase of 490.01%.
Changsha Dialine New Material Sci.&Tech.Co.Ltd(300700) : the net profit from January to February was about 6.5 million yuan, with a year-on-year increase of about 220%
Changsha Dialine New Material Sci.&Tech.Co.Ltd(300700) 3 announced on the evening of March 13 that from January to February, the company’s main business showed a good growth trend. According to the company’s preliminary accounting, from January to February 2022, the company realized an operating revenue of about 72 million yuan, a year-on-year increase of about 155%, and a net profit attributable to shareholders of listed companies of about 6.5 million yuan, a year-on-year increase of about 220%.
